TBVAC2020 : advancing tuberculosis vaccines from discovery to clinical development

Simple item page
dc.contributor.authorKaufmann, Stefan H. E.en_ZA
dc.contributor.authorDockrell, Hazel M.en_ZA
dc.contributor.authorDrager, Nicken_ZA
dc.contributor.authorHo, Mei Meien_ZA
dc.contributor.authorMcShane, Helenen_ZA
dc.contributor.authorNeyrolles, Olivieren_ZA
dc.contributor.authorOttenhoff, Tom H. M.en_ZA
dc.contributor.authorPatel, Brijen_ZA
dc.contributor.authorRoordink, Danielleen_ZA
dc.contributor.authorSpertini, Francoisen_ZA
dc.contributor.authorStenger, Steffenen_ZA
dc.contributor.authorThole, Jelleen_ZA
dc.contributor.authorVerreck, Frank A. W.en_ZA
dc.contributor.authorWilliams, Annen_ZA
dc.contributor.authorConsortium, TBVAC2020
dc.date.accessioned2018-10-09T10:06:53Z
dc.date.available2018-10-09T10:06:53Z
dc.date.issued2017-10
dc.descriptionCITATION: Kaufmann, S. H. E. et al. 2017. TBVAC2020 : advancing tuberculosis vaccines from discovery to clinical development. Frontiers in Immunology, 8:1203, doi:10.3389/fimmu.2017.01203.
dc.descriptionThe original publication is available at https://www.frontiersin.org/journals/immunology
dc.description.abstractTBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.en_ZA
dc.description.sponsorshipEuropean Union’s Horizon 2020 research and innovation programme
dc.description.urihttps://www.frontiersin.org/articles/10.3389/fimmu.2017.01203/full
dc.description.versionPublisher's version
dc.format.extent18 pages
dc.identifier.citationKaufmann, S. H. E. et al. 2017. TBVAC2020 : advancing tuberculosis vaccines from discovery to clinical development. Frontiers in Immunology, 8:1203, doi:10.3389/fimmu.2017.01203.
dc.identifier.issn1664-3224 (online)
dc.identifier.otherdoi:10.3389/fimmu.2017.01203
dc.identifier.urihttp://hdl.handle.net/10019.1/104549
dc.language.isoen_ZAen_ZA
dc.publisherFrontiers
dc.rights.holderAuthors retain copyright
dc.subjectTuberculosis vaccinesen_ZA
dc.titleTBVAC2020 : advancing tuberculosis vaccines from discovery to clinical developmenten_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
kaufmann_tbvac2020_2017.pdf
Size:
1.21 MB
Format:
Adobe Portable Document Format
Description:
Download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.95 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Molecular Biology and Human Genetics)